First-time clinical study tests a noninvasive treatment for Tourette's using an oral orthotic device
Tourette’s syndrome, first diagnosed in 1885, currently has no cure, and its etiology is still unclear in the medical community. Dr. Timothy Hottel describes a study intended to provide medical and dental teams with the ability to mitigate the clinical manifestations of Tourette’s. This is the first time a clinical study of this type has been done testing a noninvasive treatment for Tourette’s. The study will treat patients using an oral orthotic device against a placebo device.
Georges Gilles de la Tourette, a French physician and neurologist, first diagnosed Tourette’s syndrome in 1885. Research in 1972 argued that Tourette’s is a neurological disorder, not a psychological disorder. Since the 1990s, Tourette’s has been considered a neuropsychiatric condition.
Tourette’s usually has a childhood onset, characterized by multiple motor tics and one or more vocal tics. Tics are sudden, repetitive vocalizations and nonrhythmic movements of the body. They typically wax and wane, and are usually preceded by a premonitory urge.
ADDITIONAL READING |Clinical study researches use of oral appliances in mitigating severity, frequency of motor and vocal tics
With poor or inadequate management of these symptoms, patients are often socially isolated, emotionally distressed, have difficulty in school, and problems keeping a job or sustaining a career. Some experience physical pain from intense and complex tics.
Current treatments consist of antipsychotic and adrenergic agonist medications, Comprehensive Behavioral Intervention for Tics (CBIT) therapy, and Deep Brain Stimulation with varied responses patient by patient.
This syndrome currently has no cure, and the etiology is still unclear in the medical community. However, it is the intention of our study to provide medical and dental teams with the ability to mitigate the clinical manifestations of Tourette’s.
We propose in this clinical study to evaluate 65 patients, adults, and children with a confirmed medical diagnosis of Tourette’s or Chronic Tic Disorder. We will treat the patients using the oral orthotic device (much like a modified grinding or night guard) developed by TicTocStop, Inc., against a placebo device. We will monitor the patients’ dental and oral health, measure their baseline symptoms, and compare these findings after utilization of the active oral orthotic device and a placebo. There will be a single crossover after one week and a 10-week follow-up with the active device.
This is the first time a clinical study of this type has been done testing a noninvasive method of treatment for Tourette’s. Funded with $340,000 from TicTocStop, the study began in September 2014 and will run through mid-2015.
Timothy L. Hottel, DDS, MS, MBA, is dean of the College of Dentistry at the University of Tennessee Health Science Center. He previously held senior-level positions at Nova Southeastern University in Fort Lauderdale-Davie, Florida. Dr. Hottel has received a variety of university and teaching awards and donated a tremendous amount of time and energy to community service. In addition, he has authored, edited, or contributed to nearly 100 journal articles, abstracts, poster presentations, books, industry publications, and graduate thesis committees. You may contact him by email at firstname.lastname@example.org.